Search Results

You are looking at 51 - 60 of 265 items for :

  • "expectancy" x
  • Refine by Access: All x
Clear All
Full access

Palliative Care, Version 1.2014

Michael H. Levy, Thomas Smith, Amy Alvarez-Perez, Anthony Back, Justin N. Baker, Susan Block, Shirley N. Codada, Shalini Dalal, Maria Dans, Jean S. Kutner, Elizabeth Kvale, Sumathi Misra, William Mitchell, Todd M. Sauer, David Spiegel, Linda Sutton, Robert M. Taylor, Jennifer Temel, Roma Tickoo, Susan G. Urba, Carin Van Zyl, Sharon M. Weinstein, Mary Anne Bergman, and Jillian L. Scavone

care needs on a regular basis. Screening should include evaluation of the following: uncontrolled symptoms; moderate-to-severe distress related to cancer diagnosis; serious comorbid physical and psychosocial conditions; life expectancy of less than 6

Full access

Management of Elderly Patients With Cancer

Arti Hurria

cognitive impairment associated with cancer treatment weighs heavily on the minds of older patients. For instance, more than 200 older persons with a limited life expectancy due to different diseases were surveyed about their attitudes toward the burden of

Full access

NCCN Guidelines and Their Impact on Coverage Policy

William T. McGivney

-threatening diagnosis of cancer, denial of a drug with evidence supporting its use was a major concern and serious threat to that patient's life expectancy. Conversely, if a compendium indicated a use was appropriate or was listed, the private payer had to cover that

Full access

Bilateral Risk-Reducing Oophorectomy in BRCA1 and BRCA2 Mutation Carriers

Susan M. Domchek, Jill E. Stopfer, and Timothy R. Rebbeck

D Kuntz KM Garber JE Weeks JC . Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations . N Engl J Med 1997 ; 336 : 1465 – 1471 . Erratum appears in N Engl J Med 1997

Full access

Dances With Denial: Have Medical Oncology Outpatients Conveyed Their End-of-Life Wishes and Do They Want To?

Amy Waller, Charles Douglas, Rob Sanson-Fisher, Nicholas Zdenkowski, Angela Pearce, Tiffany Evans, and Justin Walsh

patient's self-reported cancer type and perceived cancer status, and personal estimation of life expectancy. Perceived cancer status was based on responses to the question, “Where are you in your cancer journey?” The response options were “I am receiving

Full access

Ten Years of Progress in Prostate Cancer

James L. Mohler

PSA tests performed in the past year. 4 The urologic community has been criticized for overuse of PSA in men older than 80 years, when life expectancy has fallen to 8 years and the chance of dying of prostate cancer, if it is detected by PSA, is less

Full access

Prostate Cancer, Version 2.2014

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Timothy M. Kuzel, Richard J. Lee, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Edward Schaeffer, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Dorothy A. Shead, and Maria Ho

prevalent cancer. However, early detection and treatment of prostate cancers that do not threaten life expectancy result in unnecessary side effects, which impair quality of life and increase health care expenses, while decreasing the value of PSA and

Full access

Impact of an NCCN-Compliant Multidisciplinary Conference on Treatment Decisions for Localized Prostate Cancer

Ahmed A. Hussein, Umar Iqbal, Zhe Jing, Yousuf Ramahi, Holly Houenstein, Stephanie Newman, Blake Peterson, Katarina Krajacic, Adeena Samoni, Bo Xu, Norbert Sule, Gissou Azabdaftari, Eric C. Kauffman, James L. Mohler, Michael Kuettel, and Khurshid A. Guru

health organizations and oncology societies to facilitate standardized and optimal care for patients. In prostate cancer, these guidelines have aimed to avoid overtreatment of cancers that are unlikely to affect a patient’s life expectancy or quality of

Full access

Palliative Care

Michael H. Levy, Michael D. Adolph, Anthony Back, Susan Block, Shirley N. Codada, Shalini Dalal, Teresa L. Deshields, Elisabeth Dexter, Sydney M. Dy, Sara J. Knight, Sumathi Misra, Christine S. Ritchie, Todd M. Sauer, Thomas Smith, David Spiegel, Linda Sutton, Robert M. Taylor, Jennifer Temel, Jay Thomas, Roma Tickoo, Susan G. Urba, Jamie H. Von Roenn, Joseph L. Weems, Sharon M. Weinstein, Deborah A. Freedman-Cass, and Mary Anne Bergman

) moderate to severe distress related to cancer diagnosis and therapy; 3) serious comorbid physical, psychiatric, and psychosocial conditions; 4) life expectancy of 6 months or less; 5) patient or family concerns about the disease course and decision

Full access


, Asia, the Middle East, and Russia. To access these resources, or to learn more about NCCN International Initiatives and international programming opportunities, visit . Changing the Course of Prostate Cancer Treatment: Life Expectancy